Assessment uncovers operating properties of disease activity measures in Crohn's disease, highlighting the performance of combined endoscopic and clinical endpoints.
Regulatory guidance for Crohn's disease trials recommends coprimary efficacy end points that evaluate both symptoms and mucosal inflammation. We aimed to characterize the operating properties of commonly used disease activity assessments alone and in combination.
No takes yet. Share an insight, caveat, or question.
Khanna et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: